June 1, 2015 8:12 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Onconova Therapeutics, Inc. (Nasdaq: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of clinical data on rigosertib in HR-MDS at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, May 29 - June 2, 2015.The poster presentations by Dr. Lewis R. Silverman of Mount Sinai Hospital and his co-authors provide detailed results from the Phase 3 ONTIME trial of IV rigosertib in HR-MDS, highlighting important subgroups and prognostic factors favoring activity of rigosertib in HR-MDS patients previously treated with hypomethylating agents (HMAs). The significance and brief summaries of the presentations are listed below."These clinical data provide the foundation for the design of a new pivotal study in HR-MDS by identifying patients who are likely to respond to IV rigosertib," said Ramesh Kumar, Ph.D., President and CEO of Onconova. "We continue to anticipate, pending receipt of appropriate financing, initiating this Phase 3 trial in 2015." International Prognostic Scoring System-Revised (IPSS-R) provides an objective predictor of survival benefit in post-HMA HR-MDS patients treated with IV rigosertib
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.